Stocks and Investing
Stocks and Investing
Fri, March 17, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
David Nierengarten Maintained (TSVT) at Buy with Decreased Target to $21 on, Mar 17th, 2023
David Nierengarten of Wedbush, Maintained "2seventy bio, Inc." (TSVT) at Buy with Decreased Target from $28 to $21 on, Mar 17th, 2023.
David has made no other calls on TSVT in the last 4 months.
There are 3 other peers that have a rating on TSVT. Out of the 3 peers that are also analyzing TSVT, 0 agree with David's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with David
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $28 on, Tuesday, January 24th, 2023
- Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $28 on, Friday, January 20th, 2023
- Daina Graybosch of "SVB Leerink" Maintained at Buy with Decreased Target to $34 on, Tuesday, January 10th, 2023
Contributing Sources